Education
About Us
Working with TipRanks
Follow Us
Getinge AB (GNGBY)
OTHER OTC:GNGBY
GNGBY Stock Chart & Stats
$22.97
$0.02(0.10%)
At close: 4:00 PM EST
$22.97
$0.02(0.10%)
Day’s Range― - ―
52-Week Range$15.67 - $24.04
Previous CloseN/A
Volume7.12K
Average Volume (3M)149.00
Market Cap
$6.30B
Enterprise Value$6.80B
Total Cash (Recent Filing)$302.71M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)30.8
Beta0.52
Next Earnings
Jan 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.07%
Share Statistics
EPS (TTM)0.22
Shares Outstanding254,152,370
10 Day Avg. Volume133
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)1.50
Price to Sales (P/S)1.42
P/FCF Ratio15.11
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda1.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Getinge AB News
GNGBY FAQ
What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was $15.67 and its highest was $24.04 in the past 12 months.
What is Getinge AB’s market cap?
Getinge AB’s market cap is $6.30B.
When is Getinge AB’s upcoming earnings report date?
Getinge AB’s upcoming earnings report date is Jan 27, 2026 which is in 35 days.
How were Getinge AB’s earnings last quarter?
Getinge AB released its earnings results on Oct 21, 2025. The company reported $0.218 earnings per share for the quarter, beating the consensus estimate of N/A by $0.218.
Is Getinge AB overvalued?
According to Wall Street analysts Getinge AB’s price is currently Overvalued.
Does Getinge AB pay dividends?
Getinge AB pays a Annually dividend of $0.478 which represents an annual dividend yield of 2.07%. See more information on Getinge AB dividends here
What is Getinge AB’s EPS estimate?
Getinge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Getinge AB have?
Getinge AB has 254,152,370 shares outstanding.
What happened to Getinge AB’s price movement after its last earnings report?
Getinge AB reported an EPS of $0.218 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.56%.
Which hedge fund is a major shareholder of Getinge AB?
Currently, no hedge funds are holding shares in GNGBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Getinge AB Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.55%
12-Months-Change
Fundamentals
Return on Equity
4.80%
Trailing 12-Months
Asset Growth
13.41%
Trailing 12-Months
Company Description
Getinge AB
Getinge AB is a global medical technology company based in Sweden, specializing in advanced solutions for healthcare professionals in the hospital and life sciences sectors. The company operates primarily in three areas: Surgical Workflows, Critical Care, and Life Science. Getinge's core products include surgical instruments, sterilization systems, intensive care unit equipment, and biopharmaceutical manufacturing solutions, aimed at improving patient outcomes and enhancing operational efficiency in healthcare facilities.
GNGBY Company Deck
GNGBY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong organic growth and improved margins, despite significant headwinds from tariffs and FX. Regulatory and quality improvements, along with successful strategic acquisitions, bolster the positive sentiment. However, challenges in the Life Science segment and market share losses in certain product categories are notable concerns.View all GNGBY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---